These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 18006328)

  • 21. Monoclonal antibodies against epidermal growth factor receptor in advanced colorectal carcinoma: clinical efficacy and markers of sensitivity.
    Carcereny E; Maurel J
    Rev Recent Clin Trials; 2006 May; 1(2):113-8. PubMed ID: 18473962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].
    Gainet M; Guardiola E; Dufresne A; Pivot X
    Cancer Radiother; 2003 Jun; 7(3):195-9. PubMed ID: 12834777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.
    Martinelli E; De Palma R; Orditura M; De Vita F; Ciardiello F
    Clin Exp Immunol; 2009 Oct; 158(1):1-9. PubMed ID: 19737224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the epidermal growth factor receptor.
    El-Rayes BF; LoRusso PM
    Br J Cancer; 2004 Aug; 91(3):418-24. PubMed ID: 15238978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacology of epidermal growth factor inhibitors.
    Toffoli G; De Mattia E; Cecchin E; Biason P; Masier S; Corona G
    Int J Biol Markers; 2007; 22(1 Suppl 4):S24-39. PubMed ID: 17520578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
    Cohen RB
    Clin Colorectal Cancer; 2003 Feb; 2(4):246-51. PubMed ID: 12620146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.
    Resch G; Schaberl-Moser R; Kier P; Kopetzky G; Scheithauer W; Sliwa T; Greil R; Nösslinger T; Mayrbäurl B; Thaler J
    Ann Oncol; 2011 Feb; 22(2):486-7. PubMed ID: 21239398
    [No Abstract]   [Full Text] [Related]  

  • 29. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?
    Peeters M; Price T; Van Laethem JL
    Oncologist; 2009 Jan; 14(1):29-39. PubMed ID: 19144681
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of targeted therapy in the treatment of advanced colorectal cancer.
    Fakih M
    Curr Treat Options Oncol; 2008 Dec; 9(4-6):357-74. PubMed ID: 19238551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancer.
    Watkins D; Cunningham D
    Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S47-52. PubMed ID: 18021487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.
    Ciardiello F; De Vita F
    Prog Drug Res; 2005; 63():93-114. PubMed ID: 16265878
    [No Abstract]   [Full Text] [Related]  

  • 34. Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.
    Dziadziuszko R; Jassem J
    Ann Oncol; 2012 Sep; 23 Suppl 10():x193-6. PubMed ID: 22987961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
    Brockstein B; Lacouture M; Agulnik M
    J Natl Compr Canc Netw; 2008 Aug; 6(7):696-706. PubMed ID: 18691458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal growth factor receptor-targeted therapy in colorectal cancer.
    Xu W; Jing H; Zhang F
    Front Biosci (Landmark Ed); 2016 Jan; 21(2):410-8. PubMed ID: 26709782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient-tailored treatments with anti-EGFR monoclonal antibodies in advanced colorectal cancer: KRAS and beyond.
    Ballestrero A; Garuti A; Cirmena G; Rocco I; Palermo C; Nencioni A; Scabini S; Zoppoli G; Parodi S; Patrone F
    Curr Cancer Drug Targets; 2012 May; 12(4):316-28. PubMed ID: 22385512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of anti-EGFR target therapy in colorectal carcinoma.
    Enrique AA; Gema PC; Jeronimo JC; Auxiliadora GE
    Front Biosci (Elite Ed); 2012 Jan; 4(1):12-22. PubMed ID: 22201852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer.
    De Cuyper A; Van Den Eynde M; Machiels JP
    Clin Colorectal Cancer; 2020 Jun; 19(2):65-72. PubMed ID: 32229076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
    Ciardiello F; De Vita F; Orditura M; De Placido S; Tortora G
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):501-14. PubMed ID: 14662002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.